Leonard Cohen, MD
Neurology · Aventura, FLNPI 1265427298
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $38,315 of the $61,416 with a category attached, or 62.4%. AbbVie accounts for 69.0% of it on its own, with 55 other manufacturers making up the rest. Reporting peaked in 2021 at $17,451 and has fallen 87.9% since, to $2,107 in 2025. Among neurology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,120 payments — averaging $54.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$42K
- UCB, Inc.$2K
- Eisai Inc.$2K
- Teva Pharmaceuticals USA, Inc.$1K
- Neurocrine Biosciences, Inc.$868
- Novartis$829
- plus $13K from 50 others
Across 260 payments — averaging $6388.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eisai Inc.$1.7M
- E.r. Squibb & Sons, L.L.C.$9K
What the payments were for
- Speaking & faculty fees$38,31562%
- Travel & lodging$1,6583%
- Food & beverage$21,31735%
- Education$1260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$61,416 in reported general payments places this provider in the 90th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 32 | $267,837 |
| NuplazidPimavanserin Tartrate | 45 | $267,324 |
| RytaryCarbidopa/Levodopa | 37 | $54,751 |
| RexultiBrexpiprazole | 29 | $41,275 |
| VimpatLacosamide | 12 | $41,057 |
| ZenzediDextroamphetamine Sulfate | 12 | $19,219 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $14,700 |
| Emgality PenGalcanezumab-Gnlm | 18 | $11,722 |
| FycompaPerampanel | 12 | $7,803 |
| Memantine Hcl | 220 | $4,784 |
| Rivastigmine | 12 | $4,381 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 206 | $3,838 |
| Lacosamide | 38 | $3,063 |
| Propranolol Hcl ErPropranolol Hcl | 86 | $2,911 |
| Levetiracetam | 97 | $2,551 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $868 | $267,83732 claims |
| Acadia Pharmaceuticals IncNuplazid | $519 | $267,32445 claims |
| Amneal Pharmaceuticals LLCRytary | $181 | $54,75137 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $328 | $41,27529 claims |
| UCB, Inc.Vimpat | $1,717 | $41,05712 claims |
| Eisai Inc.Fycompa | $1,673 | $7,80312 claims |
| Upsher-smith Laboratories LLCTopiramate | $392 | $60445 claims |
| Almatica Pharma LLCSertraline Hcl | $16 | $34129 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,434 neurology providers in Florida.
Other neurology in Aventura
- Julie SchwartzbardAventura$444K
- Jeffrey GelblumAventura$324K
- Stuart IsaacsonBoca Raton$3.9M
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
- Matthew BakerNaples$1.4M
- Donald NegroskiSarasota$1.4M
- Mark CascioneTampa$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.